SEC Comment Letter 0000000000-25-000432 to Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics, Inc.
Date: Jan. 15, 2025 · CIK: 0001855485 · Accession: 0000000000-25-000432
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284229
Letter
January 15, 2025 Allan J. Camaisa Chief Executive Officer Calidi Biotherapeutics, Inc. 4475 Executive Dr., Suite 200 San Diego, CA 92121 Re:Calidi Biotherapeutics, Inc. Registration Statement on Form S-3 Filed January 10, 2025 File No. 333-284229 Dear Allan J. Camaisa: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jay Yamamoto
Show Raw Text
January 15, 2025
Allan J. Camaisa
Chief Executive Officer
Calidi Biotherapeutics, Inc.
4475 Executive Dr., Suite 200
San Diego, CA 92121
Re:Calidi Biotherapeutics, Inc.
Registration Statement on Form S-3
Filed January 10, 2025
File No. 333-284229
Dear Allan J. Camaisa:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jay Yamamoto